TH1801006469A - Immunostimulation or modulation via globo series antigens (CANCER IMMUNOTHERAPY BY IMMUNE ACTIVATION OR IMMUNE MODULATION VIA GLOBO SERIES ANTIGENS) - Google Patents

Abstract

Page 1 of the number 1 page, a summary of the invention. Disclosure provides a method of immunotherapy for cancer patients. Consists of vaccine administration against globo series antigens. (that is, globo H, embryo antigen specific to stage 3 SSEA3” and embryo antigen specific to stage 4 SSEA4”) specifically. The composite approach involves the administration of H-KLH globular (OBI-822) in patients with diffuse breast cancer. The disclosure also provides a method of combining with the selection of suitable cancer patients as therapeutic options for immunotherapy. in addition Disclosure provides a therapeutic substance. that includes monoclonal antibodies (mAbs) that bind specific to globo series antigens. and correlated biological markers useful in targeting therapeutic combinations. and the official diagnosis ------------ Page 1 of the number 1 page summary of the invention. The disclosure provides a method of immunotherapy for cancer patients, including the administration of a vaccine against globo series antigens. (i.e. globo H, stage 3 SSEA3-specific embryo antigen” and stage 4 SSEA4-specific embryo antigen”). -KLH (OBI-822) in patients with cancer diffuse breast Disclosure is also provided by method of compositing by choice. Cancer patients who are suitable as treatment options for immunotherapy In addition, the disclosure provides a therapeutic substance. that includes specific binding monoclonal antibodies (mAbs) Specific to globo series antigens and correlated biological markers that are useful in targeting therapeutic set and the official diagnosis

Claims (70)

Page 1 of 8 Pages Claims 1. A method for the treatment of breast cancer that includes the administration of a person in need of an effective dosage. as therapeutic effects of globosyris antigen and/or cross-reactivity with globo series antigen vaccine. 2. Claim Method 1, where globosy!'s antigen-containing globose antigens are conjugated with carrier proteins, 3. Claim Method 2. where the globosy antigen consists of a selected H globo antigen, a stage 3 embryo-specific antigen (SSEA3) and a stage 4 embryo-specific antigen ( SSEA4) 4. Claim Method 2, where KLH-containing carrier proteins (key hollympet hemozyanin), DT-CRM 197 (toxin cross-reactive material) diphtheria 197), diphtheria toxoid or tetanus toxoid 5. Method of Claim 1 that Globosy Antigen vaccine is administered as a pharmaceutical component. 6. Claim Method No. 6, where the pharmaceutical composition includes H-KLH and adjuvant. 7. Claim Method 6, where the adjuvanh is selected from SA. Ponin, Frost Adjuvant or 0!-Galactocil-Ceramide (CK-GalCer) Adjuvant 8. Method of Claim 5, Where Pharmaceutical Ingredients included OBI-822/OBI-821 9. The method of claim 1 in which the immunological reactions generated by such administration are characterized by Immune response induced by globose antigen, globosy! antigen, and/or carrier protein 10. Claim Method 1, where a person is a human 11. Claim 1 method, where the therapeutic effective dose is less than 100 mcg 12. Claim 1 method, where the administration procedure consists of intramuscular injection, subcutaneous injection, intravenous injection, intraperitoneal injection, arterial injection, intra-articular injection, intrathecal injection, intrathecal injection or injection into the pleura 13. Claim 1 method, where the vaccine is administered intermittently at intervals of one week to five years. or more than page 2 of number 8 on page 14. Method of claim 1 that the vaccine is administered once every week, once every two weeks, once every three weeks, or This is once every four weeks, once every five weeks, once every six weeks, once every seven weeks, once every eight weeks, once every nine weeks, one once every ten weeks, once every twelve weeks or once every twelve weeks 15. Methods for the treatment of tumors in patients 16. Methods of Claim that 15 Where the gosbosi antigen vaccine combines the conjugated gosbosi antigen with the carrier protein 17. Claim method 16 The antigens are composed of gosbo H-selected antigens, stage 3 embryo-specific antigen (SSEA3) and stage 4 embryo-specific antigen (SSEA4). Claim 16 KLH-containing carrier protein (key'hollympet hemocyanin), DT-CRM 197 (cross-reacting material with diphtheria toxin!97). , diphtheria toxoid or tetanus toxoid 19. Method of Claim 15 where the Gosbosy antigen vaccine contains H-KLH and the Jungos adjuvants. Bose!'s Antigen 20. Claim Method 19 at the Adjuvant is chosen from Saponin, Freund Adjuvant or 0!-galactosyl-C. Ramide (Q!-GalCer) Adjuvant 21. Method of Claim No. 15 at the Gosbosi Antigenic Vaccine including OBI-822/OBI-82122. Method of Claim 15 where the Gosbosy Antigen Vaccine is composed of OBI-822 and a pharmaceutically acceptable line of drugs. 23. The method of claim 15 in which the immunological reactions produced by such administration are characterized by Immune response induced by Gosbosie's antigen, Gosbosie's antigen, and/or carrier protein24. Method of Claim 15 where Gosbosie's Vaccination Suspends antigen or cross-reactivity with Gosbosi antigen vaccine induces immunogenic production of monoclonal antibodies. Directed to Gosbosi Antigen 25. Method of claim 24 where antibody is produced is IgG, IgM, or both, page 3 of number 8, page 26. Method of claim 15. where tumors are breast cancer, lung cancer, esophageal cancer, cervical cancer, cholangiocarcinoma, liver cancer, buccal cancer, stomach cancer, colon cancer, colon cancer, pharyngeal cancer, kidney cancer, Prostate cancer, ovarian cancer, cervical cancer, uterine cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, perineal cancer Adrenal cancer, thyroid cancer, bone cancer, gallbladder cancer, oral pharyngeal cancer, laryngeal cancer, skin cancer, basal cell carcinoma, squaremus cell carcinoma Noma, Melanoma or Brain Tumor 27. Claim Method 15 where the tumor is diffuse. 28. Method of claim 15 to 23, where globosyl antigen vaccine or cross-reactivity with globo series antigen is administered to patients in combination. with anti-aging agents 29. The method of claim 28, where antiproliferative agents are selected from cyclophosphamide, opiate, colony granulocyte activation factor. (GCSF), Estrogen Inhibitor, Aromatase Inhibitor, Pituitary Gland Reductor, Tamoxifene-Specific Antigen Receptor Modulator, Rolasic Fen, Estrogen Receptor Decreased Regulators, Anticoagulants, Enzymes, Hematoproitic Growth Factors, Anticancer Agents, Antimetabolites, Other cytotoxic agents, vinca alkaloids, epi'podopylotoxins, alkylating agents, taxanes, antitumor antimicrobial agents, CAM Ptothichin, Nitrozourea, HER1/EGFR Tyrosine Kinase Inhibitor, Protein Inhibitor VEGF, HER-2/ErbB2 inhibitors, interfronts, intercikines, monoclonal antibodies or glucocorticoid steroids30. Claim method 28 that 'in which antiproliferative agents were selected from erlotinib, docchitaxil, gemchitabin, cysteplatin; carboplatin; Plachitacchil, Trastuchumab, Timozolomid, Tamoshifen, Sorubicin, Oxaliplatin, Bortizomib , citrate, litrozole, imatinib, micellate, MEK inhibitors, pilvestrant, leucovorin (folinic acid); Rapamycin, Lapati nib, Lonafarnib, Soratinub, Cititenib, Irinotikan, Tipiparnib, Cremophor-free , paclitaxil, vantitanib, chlorambuchil, temchirosimus, pasopanib, canphosamide, thiohipa, psycho lphosphamide, r-fluorouracil (5-FU), vinorelbene, novantrone, tiniposide, idatrizate, star nomycin , aminoptyrin, capizitabine, ibandronate, topoisomerase inhibitor RFS 2000, difluoromethyllornithine (DMFO ), Tadomshifen, Ralochipin, Droloshipin, 4-Hydroxytamo Shifen, Troshipin, Keoshipin, Onapris Tone, torimifene citrate, 4(5)-imidazole, aminoglutamide, migestrol acetate, echimistrene, for Mistani, Fadrozol, Vorozole, Litrozol, Anastrozole, Flutamide, Nileutamide, Bicalyutamide, Leuprolide, Kochiri. Sin, throsashitapine (CX-p. 4 of number 8 p.1,3- dioxolenenucleoside cytosine analogues), lipid kinase inhibitor, obli Merchant, Angiozyme, Allovegdin, Leu Iwdin, Vacid, Aldes Leukin, Lertotican, Abarelix. , Bivaciziumab, Alemtiuszeumab, Bivaciziumab, Citusimab, Panituimab, Rituzimab, Pertuciumab, T rastheuciumb, toxytumomab, gemtheuciumb, or ozokamycin 31. Methods for the treatment of individuals afflicted with cancer by immunosuppressive therapies that include Administering the person in need of the substance with a therapeutic effective amount of an immunogenic substance and/or cross-reacting with a beneficial immunogenic agent. For induction or modulation of immune responses 32. Method of Claim 31 that binds to globosyrus-containing immunogenic agents. Conjugated antigens with carrier proteins 33. Method of claim 32 in which globosyres antigens are composed of antigens chosen from globo H, the embryo antigen. Stage 3-specific (SSEA3) and stage 4-specific embryonic antigens (SSEA4) 34. Claims 32 method that binds carrier proteins to KLH (key' hollimpet hectare) Moshyanin), DT-CRM 197 (cross-reaction material with diphtheria toxin!97), diphtheria toxoid or tetanus toxoid 35. Method of claim 31 at the outlet. The immunogenic substance is OBI-822 and its correlation variable 36. Claim 31 method in which the immunological reaction is induced by The administration was characterized by an immune response by globosies antigen, globosy!'s antigen and/or carrier protein 37. Method of Claim 31 at an individual. 38. The method of claim 31 that the immune response consists of IgG, IgM or cell-induced responses. 39. The method of claim 38 at which the cell is a B cell or T cell 40. The method of claim 31 at which this method is annexed further by improving the survival of 41. The method of claim 40 that 'survival' consists of overall survival and/or survival. free from disease 42. The method of claim 40 that modulates the globosyl antigen reaction is further consolidated with debt. A) Induction of antibody-dependent cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). for tumor killing; Antibody-dependent (ADCC) and complement-dependent cytotoxicity (CDC);c) induction of anti-globo-series antibody-antibody binding to globosyl. Antigen-ceramides released from tumor cells to block transylin-associated factor X-dependent vascular proliferation (TRAX);d) anti-globo induction. Antigen antibody series to block immune suppression notch-dependent globosies are induced by globosies antigen-ceramides and therefore complement the T cell proliferation and cytokinesis;e) induction. lead of anti-globosies antigenic antibody to lead to apoptosis;f) inhibition of vascular genesis induced by globo series antigen; or g) OBI-822 vaccination induces apoptosis.43.Method for inducing/enhancing the immune response in individuals. including the administration of immunogenic agents and/or cross-reactivity with immunogenic agents 44. Method of claim 43 where the immunogenic substance Munogens are globoseral antigens that are Conjugated with carrier proteins. 45. Method of claim 44, where globosyl antigens are composed of antigens selected from globo H, embryonic antigens specific to the phase. 3 (SSEA3) and stage 4 embryo-specific antigen (SSEA4)46. Method of claim 44, where the carrier protein combines with KLH (key hollymphetate hemocyanin ), DT-CRM 197 (cross-reacting material with diphtheria toxin!97), diphtheria toxoid or tetanus toxoid 47. Method of claim 43, where the immature substance The munogen is OBI-822 and its correlation variant 48. Claim 43 method, where immunological reactions are induced by Such administration is characterized by an immune response by globoseril antigen, globoseril antigen, and/or carrier protein49. Method of claim 43 where the individual is a human face. 6 of 8 p.50. Method of claim 43 that the immune response is cellular immunity or Antibody Immunity51. Method of improving immune response induced by OBI-822 vaccine. In individuals in need of a drug containing: administration of an effective immunogenic amount of a pharmaceutically acceptable drug combination containing OBI-822 and one One or more of the following chosen from: a) Two or more vaccination administrations (for example, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more). ;b) adjustments to the interval and/or number of dose combinations between two consecutive administrations;c) modulation of the route of administration and/or modification of the injection site of administration; or d) any combination of the above so that each administration increases the antibody immune response and/or increases the antigen-antibody binding attraction. Injections can be modified and/or supplemented with the addition of immune response stimulants 53. The method of claim 51 that the immune response is intracellular or immunomodulatory. Antibody Immunity 54. Method of claim 51 that the immune response consists of IgG, IgM, or cell-induced response. 55. Method of Claim 54 at Cell 1 is B cell or T cell 56. Method of Claim 51 where Person is Human 57. Method of Patient Identification at Cell Appropriate for cancer therapy in need of those that include: a) administration of the effective dose of globosyrus antigen vaccine to such patients; b) assessment of the immune response of the such patients;c) determination of the expression of the globo series antigen in each patient; and d) classification of patient suitability based on indices of immune response and expression of globoseries antigens; The index is an indicator of such patients with a good predictor of recovery, page 7 of number 8, page 58. Claim Method 57 at Zongsbosyr Vaccine. Globo series antigens that are conjugated with proteins Carrier 59. Claim method 58 in which the globoserole antigen is composed of antigens selected from the globo H, phase 3 embryo-specific antigen (SSEA3) and Stage 4-specific embryo antigen (SSEA4)60. Claim method 58 that binds carrier proteins incorporating KLH (key'hollympet hemochyanin), DT-. CRM 197 (cross-reaction material with diphtheria toxin!97), diphtheria toxoid, or tetanus toxoid 61. Method of claim 57 at the Globoseril Antigen Vaccine. It is administered as a pharmaceutical component 62. Claim method 61 where the pharmaceutical constituents include GloboH-KLH and an adjuvant. are selected from the Saponin, Freund Adjuvant or Of-Galactosyl-Ceramic (Gf-GalCer) Adjuvant 64. Method of Claim No. 61 at Song composition, pharmaceutical components include OBI-822/OBI-82165. Claim 57 methods of congenital cancer are mammary cancer, lung cancer, esophageal cancer, retinal cancer, uterine cancer, bile duct cancer, necrotic cancer, buccal cancer. , stomach cancer, colon cancer, colon cancer, pharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, intrauterine cancer, malignant adenocarcinoma, testicular cancer, gastric cancer Wa, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, marrow cancer, bone cancer, gallbladder cancer, oral pharyngeal cancer, laryngeal cancer, carcinoma Skin, basal cell carcinoma, square musculoskeletal carcinoma, melanoma or brain tumor66. Claim 57 method of cancer is breast cancer. 67. The method of claim 66 on breast cancer is stage I, II, III, ER(+), PR(+), HER2(+), triple negative, diffuse or non-diffuse. Figure 68. Claims 57 methodology that spans the index of immune response includes assessments of IgG titrators, IgM titrators, disease-free survival. (PFS) and/or Overall survival (OS) 69. Methods for determining the prognosis of cancer treatment and/or drug response of patients in need of that include: a) Identify those diagnosed with cancer; p. 8 of 8; b) Determination of the degree of immune response by evaluating the appropriateness of such patients after treatment of Claim 1;c) Analysis of information obtained from claims 5770. The method of claim 69 at the tumor site is mammary carcinoma, lung cancer, esophageal cancer, reggaeton carcinoma, cholangiocarcinoma, blackout cancer, buccal cancer, gastric cancer, can cancer, colon cancer, pharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, uterine cancer, benign cancer, testicular cancer, bladder cancer, head cancer and throat, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, gallbladder cancer, oral pharyngeal cancer, laryngeal cancer, skin cancer, basal Carcinoma Cell, Square Mussel Carcinoma, Melanoma or Brain Tumor ------------ Page 1 of 8 pages Claims 1. Methods for the treatment of breast cancer that include administration of the person in need of such an effective dosage as therapeutic effects of globosy ries antigen and/or cross-reactivity with globo series antigen vaccine. 2. Claim method 1, where the globosy antigen-containing vaccine Rees antigens conjugated with carrier proteins 3. Claim method 2, where the globo series antigens are composed of globo-series antigens. Selected from globo H, stage 3-specific embryo antigen (SSEA3) and stage 4-specific embryo antigen (SSEA4). 4. Claim Method 2, where KLH-containing carrier protein (key hollymphet hemozyanin), DT-CRM 197 (cross-reacting material with diphtheria toxin 197), diphtheria toxoid or tetanus toxoid 5. Claim Method 1, where the globosomes antigen vaccine is administered as a pharmaceutical component. 6. Claim Method No. 5, where the pharmaceutical constituents include H-KLH and adjuvants. 7. Claim Method 6, where the adjuvant is chosen from the saponin, Freund adjuvant or the chemical-galactosyl-syramid formula. (Chemical formula-GalCer) Adjuvant 8. Claim Method No. 5, where pharmaceutical constituents include OBI-822/OBI-821. 9. The method of claim 1, where the immunological reactions generated by the administration It is characterized by Immune response induced by globosy vaccine. Rees antigen, globo series antigen and/or carrier protein 10. The method of claim 1 where the person is human 11. Claim Method 1, where the therapeutic effective dose is less than 100 mcg. 12. Method of claim 1 where the administration procedure consists of intramuscular injection, subcutaneous injection, intravenous injection, intraventricular injection, intravascular injection. erythema, intra-articular injection, cerebrospinal fluid injection, pericardial injection, or pleural injection 13. Method of Claim 1, where the child vaccine is administered intermittently at a certain interval. Week to five years or more Page 2 of 8 pages 14. Claim Method 1 where the vaccine is administered once every one week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks. , once every seven weeks, once every eight weeks, once every nine weeks, once every ten weeks, once every twelve weeks or once every twelve weeks 15. Methods for the treatment of tumors in patients that includes the administration of the patient Pharmaceutically effective amounts of globo series vaccine antigens and/or cross-reactivity with globo series antigens. 16. Method of claim 15, where the globo-series antigen-containing vaccine Bo series antigens conjugated with carrier proteins 17. Method of claim 16, in which the globo series antigen vaccine includes Antigens are selected from the globo H, stage 3 embryo-specific antigen (SSEA3) and stage 4 embryo-specific antigen (SSEA4). 18. Method of claim 16, where KLH-containing carrier protein (key hollymphet hemozyanin), DT-CRM 197 (cross-reacting material with diphtheria toxin 197), diphtheria toxoid or tetanus toxoid 19. Claims 15th method, where the globo series antigen consists of H-KLE1 and adjuvanh, where the globo series antigen 20. Claim method 19 where adjuvanh is chosen from saponin, Freud adju vanh or the chemical formula-galactosyl-ceramide. (Chemical formula-GalCer) Adjuvanh 21. Method of Claim 15, where Globoseris antigen vaccine contains OBI-822/OBI-821. 22. Method of Claim 15, where the globo series antigen includes OBI- 822 and a pharmaceutically acceptable line of drugs. 23. Method of claim 15, where an immunological reaction is generated by Such management is characterized by immune response induced by vaccine globo series antigen, globo series antigen and/or carrier protein 24. Method of claim 15, where the globo series antigen vaccine or cross reaction With antigen-induced globo-series vaccines, the production of monoclonal antibodies is immunogenic. Directly towards Globo Series Antigens 25. Method of claim 24 where antibodies are produced are IgG, IgM, or both, page 3 of number 8. 26. Method of claim 15 where tumors are breast cancer, lung cancer, esophageal cancer, regtum, cholangiocarcinoma, liver cancer, buccal cancer, gastric cancer, colon cancer, Colon cancer, pharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, uterine cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, perineal cancer Nervous system endocrine, adrenal cancer, thyroid cancer, bone cancer, gallbladder cancer, oral pharyngeal cancer, laryngeal cancer, skin cancer, bell cell carcinoma, square Carcinoma, melanoma, or brain tumor 27. Claim Method 15, where the tumor is diffuse. or not dispersed 28. Claim method 15 to 23, where globoseril antigen or cross-reactivity with globoseril antigen is administered to the patient in combination with antibodies. number of one or more 29. Claim method 28, where antiproliferative agents were selected from cyclophosphami, opiate, colony granulocyte activation factor (GCSF). ), estrogen inhibitor, aromatase inhibitor, pituitary reducing regulator, tamoxifen-specific antigen receptor modulator, rolazifen, Estrogen Receptor Decreased Regulators, Anticoagulants, Enzymes, Mautoprootic Growth Factors, Anticancer Agents, Antimetabolites, Toxic Substances Against other cells, vincaal alkaloids, epipodophyllotoxin, alkylating agents, taxanes, anti-tumor antigen, camptothixin N, nitrozourea, HER1/EGFR tyrosine kinase inhibitor, VEGF protein inhibitor, HER-2/ErbB2 inhibitor, interferon, interleukin, monoclonal antibody, or glucocorticoid steroid 30. Method of claim 28, where antibodies are selected from erlotinib, doxytaxil, gemcitabine, cisplatin; carboplatin; Placitaxil, Trastyusumab, Timo Solomile, Tamoxifen, Dorubicin, Oxaliplatin, Bortisomib, Siu Tentant, litrozole, imatinib, micellate, MEK inhibitor, falvestrant, leucovorin (folinic acid); Rapamycin, Lapati nib, Lonafarnib, Sorafinib, Gifhitinib, Irinotican, Tipifarnib, Cremov-free Nor, Pak Litaxil, Vantitanib, Chlorampuyl, Temperolimus, Pasopanib, Canfosamile, Thiothipa, Cycloves. Asfamile, 5-fluorouracil (5-FU), vinorelbene, novantrone, tiniposide, idatrizate, donomycin, aminoptyrin, capizitabine, ibandronate, topoisomeres inhibitor RFS 2000, difluoromethyllornithine (DMFO), Tadomsifen, raloxifin, drolosifin, 4-hydroxytamocifen, threocifin, keocifene, onapristone, torimifene citrate, 4(5)-imidazole, aminoglutithimile, migestrol acetate, eximitren, formistani, Fadrozol, vorozole, litrozole, anastrozole, flutamile, nileuthamil, baikalyuthamil, leuprolyle, goxirilin, throxacin. Tabine (chemical formula- p. 4 of number 8 p. 1,3- dioxolene nucleoside cytosine analogues), lipid kinase inhibitor, oblimersen, a. Ngiozyme, allovectin, leuvekdin, vasyd, aldesleukin, lertotican, abarelixy, bivaci suumab, a Lemthew Simamb, BiwasSiumab, SituSiamab, Panithusimamb, RituSimab, Pau Thyucew mab, tralthu siamab, tosytummab, jemthew siamab, or osokamycin. 31. Methods for the treatment of people who are hurt by cancer by medical therapy. Immunity consists of administering to the person in need of that thing by the amount available. The therapeutic efficacy of immunogenic agents and/or cross-reactivity with It is an immunogen that is useful for inducing or modulating immune responses. 32. Method of claim 31, where an immunogenic substance comprising the globo series antigens conjugated with carrier proteins 33. Claim method 32, where the globo series antigens are composed of globo-series antigens. Selected from globo H, stage 3-specific embryo antigen (SSEA3) and stage 4-specific embryo antigen (SSEA4). 34. Claim method 32, where carrier proteins are composed of KLH (key hollympet hemocyanin), DT-CRM 197 (cross-reacting material with diphtheria toxin 197). ), diphtheria toxoid or tetanus toxoid 35. Method of claim 31, where the immunogenic substance is OBI-822 and its correlation variable. 36. Method of claim 31, where an immunological reaction is produced by Such administration is characterized by an immune response by the vaccine globo series antigen, globo series antigen and/or carrier protein. 37. Method of claim 31, where the person is human 38. Method of claim 31, where the immune response is composed of IgG, IgM, or cellular-induced response. 39. Method of claim 38 where the cell is a B cell or T cell. 40. Method of claim 31, to which such methodology is further incorporated by improvements. Human survival by modulating globo-series antigen reactivity 41. The method of claim 40, where survival consists of overall survival and/or disease-free survival. 42. Method of claim 40, where modulation of globo series antigens We continue to combine with one thing. a) induction of antibody-dependent cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) for kill tumors; b) induction of the IgM/IgG antigen-series antiglobo-series immune response to induce tumor killing induced by antibody-dependent cytotoxicity (ADCC), and Complement-dependent cytotoxicity (CDC); c) induction of anti-globo-series antigen-antibody binding to globo-series. Antigen-ceramide released from tumor cells to block the proliferation of translin-associated factor X-dependent vascular (TRAX); d) anti-globo induction. Antigen antibody series to block immune suppression that depends on the Notch-1 that is induced by the antigen-ceramide globo series and therefore reinforces the increase the number of T cells and the formation of cytokines; e) induction of anti-globo series antigen antibodies leading to cell death; f) inhibition of atherogenic induced by globo series antigens; or g) OBI-822 vaccination induces apoptosis. 43. Methods for induction/enhancing the immune response in individuals, which consist of the administration of immunogenic agents and/or cross-reactivity with substances that are immunogens 44. Method of claim 43, where the immunogenic substance is the globo series antigen conjugate with carrier proteins 45. Method of claim 44, wherein the globo series antigens are composed of globo-series antigens. Selected from globo H, stage 3-specific embryo antigen (SSEA3) and stage 4-specific embryo antigen (SSEA4). 46. Method of claim 44, where the carrier protein is composed of KLH (key hollympet hemocyanin), DT-CRM 197 (cross-reacting material with diphtheria toxin 197). ), diphtheria toxoid or tetanus toxoid 47. Claim Method 43, where the immunogenic substance is OBI-822 and its related variables. 48. Method of claim 43, where an immunological reaction is produced by Such administration is characterized by an immune response by the vaccine globo series antigen, globo series antigen and/or carrier protein. 49. Method of Claim 43 Where Person is Human, page 6 of number 8. 50. Method of claim 43, where the immune response is cellular immunity or antibody immunity. 51. Methods of improving the immune response induced by OBI-822 vaccine in individuals in need of that include: The immunogenic efficacy of a pharmaceutically acceptable drug regimen containing OB1-822 and one or more of the following selected from: a) Two or more vaccine administrations. (for example, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 times or more); b) adjusting the interval and/or number of dose combinations between two consecutive administrations; c) Modification of the route of administration and/or modification of the injection site of administration; or d) any combination of the above so that each administration increases the response. Antibody immunity and/or increase the antigen-antibody binding attraction. 52. Method of Claim 51, where injections can be modified and/or supplemented by Addition of immune response stimulants 53. Method of claim 51, where the immune response is cellular immunity or antibody immunity. 54. Method of claim 51, where the immune response is composed of IgG, IgM, or cellular-induced response. 55. Claim method 54 where the cell is a B cell or T cell. 56. Method of Claim 51, where the person is human 57. Methods of identifying suitable patients for in-demand cancer therapy of that which comprises: a) administration of the effective dose of globo series antigen to such patients; b) assessment of the immune response of such patients; c) determination of the expression of the globo series antigen in each patient; and d) classification of patient suitability based on indices of immune response and globo-series antigen expression; where the index is an indicator of such patients. with a good prediction of recovery from illness, page 7 of number 8 58. Method of claim 57, where the globo-series antigen-containing vaccine Bo series conjugated ball antigens with carrier proteins 59. Claim method 58, where the globo series antigens are composed of globo-series antigens. Selected from globo H, stage 3-specific embryo antigen (SSEA3) and stage 4-specific embryo antigen (SSEA4). 60. Claim method 58, where carrier proteins are composed of KLH (key hollympet hemozyanin), DT-CRM 197 (cross-reacting material with diphtheria toxin 197). ), diphtheria toxoid or tetanus toxoid 61. Method of claim 57, where the globo series antigen vaccine is administered as a pharmaceutical component. 62. Method of claim 61, where the pharmaceutical constituents include Globo H-KLH and adjuvants. 63. Claim Method 62, where the adjuvant is chosen from the saponin, freon acju vank or the chemical formula-galactosyl-ceramide. (Chemical formula-GalCer) Adjuvant 64. Method of claim 61, where pharmaceutical constituents include OBI- 822/OBI-821. 65. Method of claim 57 where the tumor is breast cancer, lung cancer, esophageal cancer, reggaeton cancer, cholangiocarcinoma, hepatocellular carcinoma, buccal cancer, gastric cancer, colon cancer, carcinoma. Colon cancer, pharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, uterine cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, gland cancer Nervous system endocrine, adrenal cancer, thyroid cancer, bone cancer, cyst cancer, pharyngeal cancer, laryngeal cancer, skin cancer, basal cell carcinoma, square carcinoma, melanoma, or brain tumor 66. Method of claim 57 where cancer is breast cancer 67. Claim method 66, where breast cancer is stage I, II, III, ER(+), PR(+), HER2(+), triple negative, diffuse or non diffuse. 68. Method of claim 57 wherein the index of immune responses is included with assessments of IgG titrators, IgM titrators, disease-free survival (PFS) and/or overall survival (OS). 69. Methods for determining the prognosis of cancer treatment and/or the patient's drug response to that requirement include: a) identification of diagnosed patients; that it is cancer; Page 8 of 8 b) Determination of the degree of immune response by assessing the suitability of such patients after treatment of Claim 1; c) Analysis of information obtained from claim 57. 70. Method of claim 69 where the tumor is breast cancer, lung cancer, esophageal cancer, regtum, cholangiocarcinoma, liver cancer, buccal cancer, gastric cancer, carcinoma. colon, colon cancer, pharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, uterine cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, gallbladder cancer, pharyngeal cancer, laryngeal cancer, skin cancer, basal cell carcinoma , square muscle carcinoma, melanoma, or brain tumor